Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malte Kircher

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell TransplantationSabine Maurer, Peter Herhaus, Romina Lippenmeyer, et al.
EJNMMI Research|August 21, 2021
Investigation of spleen CXCR4 expression by [<sup>68</sup>Ga]Pentixafor PET in a cohort of 145 solid cancer patientsRichard Lewis, Stefan Habringer, Malte Kircher, et al.
Clinical Nuclear Medicine|July 6, 2019
Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PETOlivia Kertels, Milena I Mihovilovic, Thomas Linsenmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
<sup>68</sup>Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative NeoplasmsSabrina Kraus, Alexander Dierks, Leo Rasche, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2021
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [<sup>18</sup>F]FDG PET/CT and MRIChristian Linz, Roman C Brands, Olivia Kertels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2023
[<sup>18</sup>F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?Olivia Kertels, Jürgen Krauß, Camelia Maria Monoranu, et al.
Oncotarget|October 27, 2016
Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRIConstantin Lapa, Theresa Reiter, Malte Kircher, et al.
Cancers|August 23, 2020
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical FeaturesXiang Zhou, Alexander Dierks, Olivia Kertels, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine CarcinomasAlexander Weich, Rudolf A Werner, Andreas K Buck, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell TransplantationSabine Maurer, Peter Herhaus, Romina Lippenmeyer, et al.
EJNMMI Research|August 21, 2021
Investigation of spleen CXCR4 expression by [<sup>68</sup>Ga]Pentixafor PET in a cohort of 145 solid cancer patientsRichard Lewis, Stefan Habringer, Malte Kircher, et al.
Clinical Nuclear Medicine|July 6, 2019
Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PETOlivia Kertels, Milena I Mihovilovic, Thomas Linsenmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
<sup>68</sup>Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative NeoplasmsSabrina Kraus, Alexander Dierks, Leo Rasche, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2021
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [<sup>18</sup>F]FDG PET/CT and MRIChristian Linz, Roman C Brands, Olivia Kertels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2023
[<sup>18</sup>F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?Olivia Kertels, Jürgen Krauß, Camelia Maria Monoranu, et al.
Oncotarget|October 27, 2016
Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRIConstantin Lapa, Theresa Reiter, Malte Kircher, et al.
Cancers|August 23, 2020
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical FeaturesXiang Zhou, Alexander Dierks, Olivia Kertels, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine CarcinomasAlexander Weich, Rudolf A Werner, Andreas K Buck, et al.
Pageof 6